Identifying biomarkers for cerebral amyloid angiopathy
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA
This study is trying to find signs that show how cerebral amyloid angiopathy affects older people, to help doctors better understand and treat the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Academic / other |
| Locations | 1 site (Milan, Milano) |
| Trial ID | NCT04204642 on ClinicalTrials.gov |
What this trial studies
The SENECA project is an Italian multicenter cohort study focused on cerebral amyloid angiopathy (CAA), a significant cause of intracerebral hemorrhage and cognitive decline in the elderly. This observational study aims to define the natural history of CAA and identify clinical and neuroradiological markers that indicate disease progression. By integrating the expertise of neurologists, neuroradiologists, neuro-ophthalmologists, and biologists, the study will collect a comprehensive dataset and biorepository from well-characterized CAA patients. The findings are expected to enhance clinical management guidelines and inform future treatment development.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 55 and older diagnosed with symptomatic or asymptomatic cerebral amyloid angiopathy.
Not a fit: Patients with other causes of cerebral hemorrhage or contraindications to brain MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients with cerebral amyloid angiopathy.
How similar studies have performed: While this study is novel in its specific focus on CAA biomarkers, similar studies in related fields have shown promise in identifying disease markers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All consecutive patients ≥55 years (with the exception of genetic cases), referred to the participating centres, with a diagnosis of possible probable and definite symptomatic or asymptomatic CAA, defined according to the modified Boston neuroradiological criteria, who had undergone at least one brain MRI (mandatory requirement for inclusion of the patient in the study) will be recruited. Exclusion Criteria: * evidence of other causes of cerebral hemorrhage (brain tumors, arteriovenous malformations, aneurysms, cavernous angiomas), contraindications to brain MRI, pregnancy and breastfeeding
Where this trial is running
Milan, Milano
- UOC Neurologia 5 — Milan, Milano, Italy (Recruiting)
Study contacts
- Study coordinator: Anna Bersano, MD, Phd
- Email: anna.bersano@istituto-besta.it
- Phone: +39022394
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.